A new transmucosal fentanyl for breakthrough cancer pain

Cancer Practice

Volumn 7, Issue 6, 1999, Pages 317-320

  Rospond, Raylene M ^a  

^a DRAKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; FENTANYL CITRATE;

ANALGESIA; CANCER PAIN; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; REVIEW; SOMNOLENCE; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; FENTANYL; HUMANS; NEOPLASMS; PAIN;

EID: 0032721737     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1999.76010.x     Document Type: Review

References (16)

1. Chandler S. Oral transmucosal fentanyl citrate: a new treatment for breakthrough pain. Am J Hosp Palliat Care 1999; 16:489-491.
2. Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care 1998; 15: 13-22.
3. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990;41:273-281.
4. Abbott Laboratories. Fentanyl Oralet package insert. North Chicago, IL: Abbott Laboratories; 1993.
5. Abbott Laboratories. Actiq packet insert. North Chicago, IL: Abbot Laboratories; 1998.
6. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991;75:223-229.
7. Streisand JB, Busch MA, Egan TD et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998;88:305-309.
8. Labroo RB, Paine MF, Thrummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos Biol Fate Chem 1997;25:1072-1080.
9. Asburn MA, Fine PG, Stanley TH. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report. Anesthesiology 1989;71:615-617.
10. Fine PG, Marcus M, DeBoer AJ, et al. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991;45:149-153.
11. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16: 3238-3245.
12. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-312.
13. Farrar JT, Clearly J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:661-666.
14. Patt RB. Long-term safety and efficacy of oral transmucosal fentanyl citrate (OTFC, Actiq) for treatment of breakthrough cancer pain. American Pain Society meeting, New Orleans, LA; 1997 (abstract).
15. Cleary JF. Use of oral transmucosal fentanyl citrate as around-the-clock medication in patients with cancer. In: 16th Annual Scientific Meeting of the American Pain Society; 1997; New Orleans, LA. Abstract 606.
16. Fine PG. Clinical Experience with Actiq (Oral Transmucosal Fentanyl Citrate) for the Treatment of Cancer Pain. Today's Therapeutic Trends 1999:17:1-11.